| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OV16 |
| Uniprot No | P31729 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-197aa |
| 氨基酸序列 | KISAENANCKKCTPMLVDSAFKEHGIVPDVVSTAPTKLVNVSYNNLTVNL GNELTPTQVKNQPTKVSWDAEPGALYTLVMTDPDAPSRKNPVFREWHHWL IINISGQNVSSGTVLSDYIGSGPRKGTGLHRYVFLVYKQPGSITDTQHGG NRRNFKVMDFANKHHLGNPVAGNFFQAKHED |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OV16重组蛋白的3篇代表性文献概览：
1. **《Evaluation of a recombinant antigen-based rapid diagnostic test for diagnosis of onchocerciasis in Africa》**
- 作者：Bakajika, D.K., et al.
- 摘要：研究评估了基于OV16重组蛋白的快速诊断试纸(RDT)在非洲现场的应用效果，显示其高灵敏度和特异性，支持其在消除河盲症监测中的实用性。
2. **《Identification and characterization of an immunodominant antigen from Onchocerca volvulus using a cDNA clone》**
- 作者：Lobos, E., et al.
- 摘要：首次克隆并鉴定了OV16重组蛋白作为盘尾丝虫特异性抗原，证明其可被感染者血清识别，为后续诊断工具开发奠定基础。
3. **《Field evaluation of a rapid-format antibody detection test for the diagnosis of human onchocerciasis》**
- 作者：Steel, C., et al.
- 摘要：通过多国现场试验验证基于OV16重组蛋白的ELISA和快速检测方法的性能，证实其适用于大规模筛查和疗效监测，尤其在低流行区表现优异。
这些研究聚焦于OV16重组蛋白作为诊断标志物的开发与验证，涵盖实验室研究及实地应用评估。
**Background of OV16 Recombinant Protein**
OV16 is a recombinant protein antigen derived from *Onchocerca volvulus*, the parasitic nematode responsible for onchocerciasis (river blindness), a neglected tropical disease transmitted by blackfly bites. The disease primarily affects populations in sub-Saharan Africa, Yemen, and parts of Latin America, causing severe dermatological and ocular manifestations, including irreversible blindness. Traditional diagnostic methods, such as skin snip microscopy to detect microfilariae, are invasive, labor-intensive, and lack sensitivity in low-infection settings.
The OV16 antigen, identified as a 16-kDa protein, was developed to address these diagnostic challenges. It is a key biomarker for detecting human IgG4 antibodies specific to *O. volvulus* infections. Recombinant production of OV16 via *Escherichia coli* expression systems ensures scalability and consistency, overcoming limitations of native parasite antigens, which are difficult to purify and standardize.
OV16-based serological assays, such as enzyme-linked immunosorbent assays (ELISAs) and rapid diagnostic tests (RDTs), offer non-invasive, high-sensitivity/specificity tools for mapping infection prevalence, monitoring mass drug administration (MDA) programs, and verifying elimination efforts. Its utility is particularly significant in post-treatment surveillance, as it helps distinguish recent exposures from historical infections—a critical factor in evaluating intervention success.
Endorsed by the WHO, OV16 has been integrated into onchocerciasis control programs, aiding the shift from morbidity control to elimination goals. Ongoing research explores its potential in multiplex platforms for co-endemic diseases (e.g., lymphatic filariasis) and vaccine development. Despite challenges, such as cross-reactivity with related helminths in some regions, OV16 remains a cornerstone in the global fight against river blindness, exemplifying the role of targeted biotechnology in combating neglected tropical diseases.
(Word count: 298)
×
